ArticlePsychiatry investigation2026
A Preliminary Study on the Efficacy and Safety of a Novel Digital Therapeutic Device: A Randomized Clinical Trial in South Korean Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
Article in Psychiatry investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAttention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children. As digital therapeutics (DTx) emerge as adjuncts to traditional ADHD treatment, we evaluated the efficacy and safety of a novel game-based DTx (ADAM-101) in pediatric ADHD. We hypothesized that adding ADAM-101 to pharmacotherapy would improve ADHD symptoms and attention more than pharmacotherapy alone. This study represents one of the first multicenter DTx trials conducted in South Korea.
methodsThis prospective, multicenter, open-label randomized clinical trial enrolled 54 children aged 7-12 years with ADHD. Participants were assigned to an intervention group (pharmacotherapy+ADAM-101) or a control group (pharmacotherapy only). The intervention group used ADAM-101 for 25 minutes per session, five times a week, for 4 weeks. Primary outcomes were the Korean ADHD Rating Scale (K-ARS) and the Advanced Test of Attention (ATA). Clinical Global Impressions (CGI) scales were used as secondary outcome measures. Safety was assessed via vital signs, electrocardiography, and adverse event reporting.
resultsCompared with control, the intervention group showed significantly greater improvement in parent-rated K-ARS (Cohen's d=1.07) and the auditory ATA Sensitivity Index (d=0.61). No significant differences were observed in visual ATA measures. CGI scales also favored the intervention group (CGI-Improvement d=1.57; CGI-Severity d=1.05). No serious adverse events were reported.
conclusionADAM-101 as an adjunct to pharmacotherapy showed preliminary benefits in clinician- and parent-rated symptom severity and auditory attention, without significant safety concerns. Larger confirmatory trials are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.